MARKET WIREYahoo! Finance Canada • 1h ago
Cingulate Inc. (CING) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
Why CING Stock dropped -4.05% Today — RQD Quant Desk Flash
$4.98 -4.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.93
Cingulate Inc. (CING) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $75.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CING Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CING stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Cingulate Inc. (NASDAQ: CING) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.98 (-4.05% 1D, market cap $75.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CING ranks #646 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CING compare to ACRV and LFVN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CING carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACRV (Acrivon Therapeutics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $75.4M) and LFVN (Lifevantage Corporation (Delaware)) posts a B+ grade (76/100 RQD, P/E 7.5x, ROIC 29.2%, cap $73.9M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CING?
▼
Per CING's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001862150), Cingulate Inc. generated $0 in revenue, -$22.4M in net income, and -$17.4M in free cash flow against $15.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.93 (-0.92%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CING)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY CING SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.89-10.8% Next Q
28
Q2 (-2Q)Grade E$4.36+14.2% Next Q
31
Q3 (-1Q)Grade E$4.98+0% Next Q
33
CurrentGrade D-$4.98-8.3% Hist 90D α
36
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CING Turnaround Squeeze
While CING currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.03) and Max Pain ($5.23) forces dealer call-delta covering toward $12.48.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CING• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CING Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CING Stock dropped -4.05% Today — RQD Quant Desk Flash
Cingulate Inc. (CING) dropped -4.05% to $4.98, trading at 21% of its 52-week range ($3.16 – $11.89). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 21% of its 52-week range ($3.16 – $11.89) with RSI-14 at 51.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.98 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CING Headlines & Catalysts
MARKET WIREYahoo Finance UK • 4h ago
Cingulate Inc. (CING) Seasonal returns chartYahoo Finance UK report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 7h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), ScinaiBenzinga report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 10h ago
CING Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 6.87% - Core Business Growthhttps://www.dars.gov.et/ report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 46d ago
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging PharmaChief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size PharmaKANSAS CITY, Kan., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharm
MARKET WIREYahoo Finance • 75d ago
CING: Second Quarter ResultsBy John Vandermosten, CFA NASDAQ: CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ: CING) reported second quarter 2026 results on August 13 th , 2026. During the three-month period, the company generated n
RISK WATCHYahoo Finance • 81d ago
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial ReadinessCash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and Controls (CMC) Work Toward NDA ResubmissionKANSAS CITY, Kan., Aug. 13, 2026
CATALYSTYahoo Finance • 123d ago
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional InvestorsKANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical com
MARKET WIREYahoo Finance • 150d ago
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup
RISK WATCHYahoo Finance • 153d ago
Cingulate Receives Complete Response Letter from FDA for CTx-1301No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of Requested InformationCompany is Well Capitalized with
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CING)
- ✓Walkthrough of CING's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CING // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -3.30%▼ DESCENDING CHANNEL
2026-10-30O $5.04H $5.10L $4.84C $4.98VOL 76.7K
RES: $5.66SUP: $3.99SMA50: $5.03SMA200: $5.44
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CING Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CING today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CING. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CING today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CING)
Health Care Rank #646 of 1016
⚔️ ACRV vs CING Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CING vs. ACRV, LFVN, MAIA, SDEV)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cingulate Inc. (CING) ranks #646 by composite RQD confidence (36/100, grade D-) and #694 by equity capitalization ($75.5M). Within this direct 5-issuer industry benchmark cohort, LFVN leads on earnings valuation at 7.5x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with CING at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CING
ACTIVE
Cingulate Inc. | D- | 36/100 | — | — | -35.0% | -4.05% | $75.5M | Benchmark Subject |
| ACRV Acrivon Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -5.68% | $75.4M | /acrv-vs-cing → |
| LFVN Lifevantage Corporation (Delaware) | B+ | 76/100 | 7.5x | 80.4% | 29.2% | +0.17% | $73.9M | /lfvn-vs-cing → |
| MAIA MAIA Biotechnology Inc. | D | 48/100 | — | — | -35.0% | -6.78% | $72.9M | /maia-vs-cing → |
| SDEV Stablecoin Development Corporation | D- | 42/100 | — | — | -35.0% | -6.48% | $79.0M | /sdev-vs-cing → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001862150In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cingulate Inc. (CING) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$22.4M, operating cash flow of -$17.2M, and free cash flow of -$17.4M (+6.7% YoY). On the balance sheet, CING closed FY2025 with $15.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$22.4M | -$17.2M | -$17.4M | $15.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$16.6M | -$18.5M | -$18.7M | $14.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$23.5M | -$15.0M | -$15.0M | — | — |
3. CING Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CING stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Cingulate Inc. (NASDAQ: CING) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.98 (-4.05% 1D, market cap $75.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CING ranks #646 in composite RQD confidence.
How does CING compare to ACRV and LFVN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CING carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACRV (Acrivon Therapeutics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $75.4M) and LFVN (Lifevantage Corporation (Delaware)) posts a B+ grade (76/100 RQD, P/E 7.5x, ROIC 29.2%, cap $73.9M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CING?
Per CING's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001862150), Cingulate Inc. generated $0 in revenue, -$22.4M in net income, and -$17.4M in free cash flow against $15.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CING trading relative to its 50-day, 200-day, and 52-week technical levels?
CING last traded at $4.98 (-4.05% on volume of 76,669 shares), positioning the stock -0.99% below its 50-day simple moving average ($5.03) and -8.46% below its 200-day simple moving average ($5.44). Across its 52-week range of $3.16 to $11.89, CING sits at the 20.8% percentile with a 14-day RSI of 51.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.36 to $5.60).
CING Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CING stock moving today?
Why CING Stock dropped -4.05% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CING — Cingulate Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:45:22Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CING scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 9 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -23.06%. For an investor, this indicates the business is not currently generating returns on invested capital or positive free cash flow, so any valuation rests on expectations rather than current earnings power.
- Whale 13F Flow: 6 / 20. Per the Roarable RQD rating, this reflects institutional accumulation and options positioning. The source does not provide holder-level detail (see Analyst View), so the basis for this score cannot be independently verified from the supplied data.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. This is the lowest pillar, suggesting weak insider-side conviction in the data provided.
- Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, this reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broad market, offering no defensive cushion.
- Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, this reflects an Altman Z-Score of 2.5, Piotroski F-Score of 2/9, and Debt/Equity of 0.5. These metrics point to moderate balance-sheet stress rather than acute distress.
Taken together, a prospective investor evaluating CING today faces a company with negative returns, negative free cash flow, weak insider signals, and a balance sheet that is serviceable but not strong. Upside would depend on a change in operating trajectory that the source data does not yet show; valuation tradeoffs are difficult to assess without earnings-based multiples, which are unavailable.
Business
Cingulate Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the Profile. Per the Profile, the company carries a market capitalization of $0.1B. The source data does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M for each period shown.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-19.9M | $-22.4M | N/A | $-17.4M | $11.0M | N/A |
| FY 2024 | $0.0M | $-15.6M | $-16.6M | N/A | $-18.7M | $12.2M | N/A |
| FY 2023 | $0.0M | $-22.8M | $-23.5M | N/A | $-15.0M | N/A | N/A |
Per the SEC financials, the company reported operating losses in each period shown, and per the Market Data, gross, operating, and net margins are each 0%. Per the Roarable RQD rating, ROIC is -35%. Per the Roarable RQD rating, the forensic balance sheet metrics are an Altman Z-Score of 2.5 and a Piotroski F-Score of 2/9. Per the SEC financials, cash declined from $12.2M to $11.0M between FY 2024 and FY 2025.
Recent Catalysts & News Wire Analysis
Per the news wire, four items reference CING:
- Two Yahoo-sourced seasonal-returns and market-action reports (YELLOW, MARKET WIRE).
- A Benzinga pre-market movers report (YELLOW, MARKET WIRE).
- A report headlined as a Q2 2026 earnings result stating a narrower-than-expected loss lifted shares 6.87% (GREEN, CATALYST).
The summaries for the first three items are generic and do not contain specific fundamental detail. The single CATALYST item is the only item flagged as a catalyst; its summary field is malformed (it lists a URL rather than a description), so its content cannot be verified beyond the headline. Per the Market Data, the stock is down -4.05% on the day. Per the Butterfly Supply-Chain Graph, supply_chain is NONE, with no butterfly links and no proprietary signals.
Risk watch items: the day's price decline, the 52-week range spanning $3.16 to $11.89, and the reported lack of revenue.
Open Questions
- What are CING's products and revenue model, given reported revenue of $0.0M across all periods?
- What is the basis for the Q2 2026 narrower-loss catalyst, and what were the reported figures?
- What drove the decline in cash from $12.2M to $11.0M, and how long does that runway last at current FCF burn?
- What is the identity and size of institutional and insider holders behind the Whale 13F and Insider Conviction pillar scores?
- What is the debt position, since Debt is N/A across reported periods while Debt/Equity is cited as 0.5?
CING Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cingulate Inc. (CING) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 1h ago
Cingulate Inc. (CING) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 4h ago
Cingulate Inc. (CING) Seasonal returns chart Yahoo Finance UK report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 7h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), Scinai Benzinga report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 10h ago
CING Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 6.87% - Core Business Growth https://www.dars.gov.et/ report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 46d ago
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size PharmaKANSAS CITY, Kan., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharm
🟡 MARKET WIRE Yahoo Finance • 75d ago
CING: Second Quarter Results By John Vandermosten, CFA NASDAQ: CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ: CING) reported second quarter 2026 results on August 13 th , 2026. During the three-month period, the company generated n
🔴 RISK WATCH Yahoo Finance • 81d ago
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and Controls (CMC) Work Toward NDA ResubmissionKANSAS CITY, Kan., Aug. 13, 2026
🟢 CATALYST Yahoo Finance • 123d ago
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional InvestorsKANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical com
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CING Bull vs. Bear Conversation Board — What's Your Call at $4.98?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CING 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $4.38 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CING (D- • RQD 36/100) a Buy at $4.98?
Welcome to the CING (Cingulate Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $4.03 (-19.1%)
Spot @ $4.98 Pump the brakes on CING — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CING, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cingulate Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $6.08 (+22.1%)
Spot @ $4.98 CING cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CING, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.98 (52-wk range $3.16 - $11.89), any beat on forward guidance forces shorts and underweight funds to chase.